| This week's sponsor is Biotech Primer. | | | |
| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications. | |
|
Featured Story | | | Monday, March 12, 2018 Novartis just rejigged its executive committee for three obvious reasons: Its operations chief is leaving, it’s aiming for big things in digital and it needs to tighten focus on ethics and compliance after a series of scandals around the globe. |
|
|
Top Stories Of The Week Tuesday, March 13, 2018 The FDA has placed a clinical hold on a study of Advaxis’ axalimogene filolisbac and AstraZeneca’s PD-L1 checkpoint inhibitor Imfinzi. Regulatory officials took the action upon learning a cervical cancer patient developed respiratory failure and died after receiving the combination. Tuesday, March 13, 2018 When Andrew Witty headed up GlaxoSmithKline, he repeatedly told investors he was prepping the company for a future rife with payer pressure and cost-saving maneuvers that would hit pharma where it hurt. And now, he'll apply that pressure. Monday, March 12, 2018 As Pfizer clears house of its unwanted neuro assets, Biogen has become a buyer for one, namely a phase 2-ready schizophrenia drug. Saturday, March 10, 2018 ORLANDO, Fla.—As the American College of Cardiology's annual meeting kicked off in Orlando on Saturday, all eyes turned to Sanofi and Regeneron, who reported their PCSK9 drug Praluent reduced the risk of cardiovascular events by 15%—as well as all-cause mortality by 15%—in the outcomes trial Odyssey. Friday, March 9, 2018 About 20% of adenocarcinomas of the lung are marked by alterations in a cell signaling pathway called KEAP1/NRF2. Now scientists in Australia have learned that these aggressive tumors may respond well to immuno-oncology treatments. Thursday, March 15, 2018 Teva officials said their migraine drug fremanezumab, a linchpin of their growth plans, might not be delayed by "limited" problems at the Celltrion plant where its active ingredient would be made. But analysts say those problems likely aren't as limited as Teva might have hoped. Monday, March 12, 2018 A phase 3 trial of Zoll Medical’s LifeVest has missed its primary endpoint. The study found that people who started using the wearable defibrillator the week after they had a heart attack were as likely to suffer sudden cardiac death in the next three months as patients who received conventional therapy. Wednesday, March 14, 2018 The Centers for Disease Control and Prevention recently said flu immunizations have been about 36% effective in the U.S. this year, during a season that's been particularly severe. No wonder experts are calling for alternatives, but the "holy grail"—a flu shot that fights any strain of virus—is still years away. Friday, March 9, 2018 Artificial intelligence-driven drug discovery has attracted many investments lately. Atomwise, the first company to commercialize deep neural networks for drug discovery, joined the growing list with a $45 million series A. |
